Company Poised to Be Industry Leader in Autologous Adipose Stem Cell Treatments
SUNRISE, FL – Jan. 15, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has reached a key milestone of 10,000 kit sales of its proprietary Adipocell TM product, a direct result of its relationships with 287 clinics in the United States and 700+ physicians worldwide offering USRM’s proprietary stem cell products and services.
Adipocell TM , which has been developed, marketed and distributed by USRM, enables physicians to separate potent stem cells from a patient’s own (autologous) fat cells, which are harvested and reinserted in two-hours total, in a minimally invasive procedure. Stem cells are an important component of the body’s ability to regenerate itself, and are rapidly becoming a mainstream trend in the field of regenerative medicine.
USRM is the premiere company in the United States that markets and manufactures an autologous adipose/stem cell separation kit. Autologous cells are not rejected by the body’s immune system and, as a result, may be more compatible and effective in reversing damage and augmenting health.
In addition to trailblazing the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, USRM also has developed a training program for physicians who want to learn how to offer stem cell therapy to their patients.
In-person training involves a two-day, interactive, hands-on training course at USRM’s Sunrise, Florida-based clinic, and includes integration of autologous cellular treatments, the extraction of lipoaspirate and bone marrow aspirate, as well as demonstrations on how to isolate adipose and bone-marrow-derived stem cells. Physician trainees will participate in several cases and perform clinical procedures under the supervision of an experienced instructor on a total of 3-5 patients. Cost for physician participation is $7,500.
Online training offers physicians clinical training in a web-based format. Consistent with in-person training, online training focuses on autologous cellular treatments like adult stem cells and platelet-rich plasma. Physicians will learn the basics of stem therapy and have the option to obtain preceptor on-site training. Cost for physician participation is $2,500.
On-site training is available for physicians who have completed in-person or online training, and involves a USRM stem-cell specialist providing the physician one-on-one, on-site training at the physician’s own clinic.
“This is a key milestone for us as a Company, and for regenerative medicine in general, as it demonstrates the increasing demand in the marketplace for our AdipocellTM product,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “We are dedicated and proud to lead the way on a global scale for the emergence of this novel therapeutic.”
“Our commitment to making regenerative, stem cell therapy available to any physician worldwide who is interested in providing stem cell therapy to their patients is reflected in our day-to-day practices as an organization,” said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc. “The need for readily available stem cell procedures that physicians can offer their patients as an alternative to addictive pain medications, which has caused an opioid crisis in America, proves the time for regenerative medicine as a part of regular physician practice and pain management is long overdue.”
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.